8 Rue Lamennais
Paris
France
ARCAGY-GINECO
ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor
Ovarian cancer, neoadjuvant chemotherapy, biomarkers, homologous recombination deficiency, TILS
Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi